EULAR 2020 Highlights Brochure

Enhancing knowledge of the clinical
importance of cytokine signalling
The Cytokine Signalling Forum
www.cytokinesignalling.com
EULAR 2020
Conference Highlights
Developed under
the auspices of the
University of Glasgow
Register for all this FREE content at
www.cytokinesignalling.com

Key Presentations
Wednesday, June 3, 2020
ORAL PRESENTATIONS
Opening plenary abstract session
Isomäki, 15:00 – 16:30
LB0001
Efficacy and Safety of Upadacitinib Versus
Placebo and Adalimumab in Patients with Active
Psoriatic Arthritis and Inadequate Response to
Non-Biologic Disease-Modifying Anti-Rheumatic
Drugs (SELECT-PsA-1): A Double-Blind,
Randomised Controlled Phase 3 Trial
Pathogenic insights transforming the
treatment of Sjögren’s and SLE 2020
and beyond
Dequeker, 16:00 – 16:45
OP0045
Delineation of a Proinflammatory Cytokine Profile
Targeted by JAK1/2 Inhibition Using Baricitinib in
a Phase 2 SLE Trial
Thursday, June 4, 2020
ORAL PRESENTATIONS
Abstract session miscellaneous
Nuki, 10:15 – 11:10
OP0001
Baricitinib, Tofacitinib, Upadacitinib, Filgotinib,
and Cytokine Signalling in Human Leukocyte
Subpopulations: An Updated Ex-Vivo Comparison
Thursday, June 4, 2020
POSTERS
THU0030
THU0067
Distinct Effects of Five JAK Inhibitors in the
Modulation of Human B Cell Activation
JAK Selectivity and the Impact on Cytokine
Signalling Inhibition at Clinical Rheumatoid
Arthritis Doses
THU0073
THU0080
THU0081
THU0084
THU0149
THU0188
THU0192
THU0194
THU0195
THU0196
THU0197
THU0198
The Anti-Angiogenic Role of Tofacitinib During
Experimental Model of Arthritis
Preclinical Characterisation of TLL018, A Novel,
Highly Potent and Selective JAK1/TYK2 Inhibitor
for Treating Autoimmune Diseases
MIR-17-5p Reduces Inflammation and Bone
Erosions in Collagen Induced Arthritis Mice
and Directly Targets the JAK-STAT Pathway in
Rheumatoid Arthritis Fibroblast-Like Synoviocytes
Tofacitinib Reversed Endothelial Dysfunction in
Rheumatoid Arthritis: Mechanistic Insights from
the Rat Adjuvant-Induced Arthritis Model
JAK Kinase Inhibitors and Varicella Zoster Virus
Infection in Patients with Rheumatoid Arthritis.
Systematic Review of the Literature
Efficacy of Filgotinib in Patients with Rheumatoid
Arthritis with Poor Prognostic Factors: Post Hoc
Analysis of FINCH 3
Upadacitinib Treatment and the Routine
Assessment of Patient Index Data 3 (RAPID3)
Among Patients with Rheumatoid Arthritis
Characterisation of Depth of Response, including
50% Improvement in ACR Components at Week
12 and Remission at Week 24, Following Treatment
with Filgotinib Compared with Methotrexate or
Adalimumab in Patients with Rheumatoid Arthritis
Incidence and Risk of Venous Thromboembolic
Events Among Patients with Rheumatoid Arthritis
Enrolled in the Upadacitinib SELECT Clinical
Trial Program
Tofacitinib in Patients with Rheumatoid Arthritis
and Indicative of Depression and/or Anxiety:
A Post Hoc Analysis of Phase 3 and Phase 3b/4
Clinical Trials
Safety Profile of Upadacitinib up to 3 Years of
Exposure in Patients with Rheumatoid Arthritis
Efficacy and Safety of Filgotinib for Patients with
Rheumatoid Arthritis with Inadequate Response to
Methotrexate: FINCH 1 52-Week Results
Chairman’s picks

THU0200
THU0201
THU0202
THU0203
THU0204
THU0205
THU0206
THU0207
THU0208
THU0209
THU0210
THU0211
The Choice of bDMARD or tsDMARD as First Line
Therapy: Data of the TARDIS-RA Registry,
A Nationwide Belgian Biologic Registry
Long-Term Safety and Effectiveness of
Upadacitinib or Adalimumab in Patients with
Rheumatoid Arthritis: Results at 72 Weeks from
the SELECT-COMPARE Study
Integrated Safety Analysis of Filgotinib Treatment
for Rheumatoid Arthritis from 7 Clinical Trials
Real World Effectiveness of Baricitinib in the
Swiss Rheumatoid Arthritis Register (SCAM-RA)
A Subgroup Analysis of Low Disease Activity and
Remission from Phase 3 Study of Filgotinib in Patients
with Inadequate Response to Biologic DMARDs
Response to Small Molecules is Mostly Driven
by Patient Global Assessment of Disease: A Real
World Observation
A Very Early (7-28 Days) Response on JAK Inhibitor
Tofacitinib in Patients with Active Rheumatoid
Arthritis: Effect on Pain and Central Sensitisation
Sustainability of Response to Upadacitinib as
Monotherapy or in Combination Among Patients
with Rheumatoid Arthritis and Prior Inadequate
Response to Conventional Synthetic DMARDs
Affecting Common Biological Processes or
Disparate? Comparison of Gene-Expression
Modification Profiles Among Targeting IL-6 and
Targeting Specific JAK Treatments
Uptake of Janus Kinase Inhibitors for Management
of Rheumatoid Arthritis in Australia
Early Discontinuation of Tofacitinib in Patients with
Rheumatoid Arthritis Co-Treated with Rifampin for
Latent Tuberculosis: Results from the Real-World Data
Radiographic Outcomes in Patients with Rheumatoid
Arthritis Receiving Upadacitinib as Monotherapy or in
Combination with Methotrexate: Results at 2 Years from
the SELECT-COMPARE and SELECT-EARLY Studies
THU0213
THU0215
THU0216
THU0217
THU0218
THU0326
THU0375
THU0377
THU0385
Upadacitinib as Monotherapy in Patients with
Rheumatoid Arthritis and Prior Inadequate
Response to Methotrexate: Results at 84 Weeks
from the SELECT-MONOTHERAPY Study
Whole Blood Transcriptional Changes Following
Selective Inhibition of Janus Kinase 1 (JAK1) by
Filgotinib in Adults with Moderately-to-Severely
Active Rheumatoid Arthritis with Prior Inadequate
Response to Methotrexate (FINCH1)
Peripheral Protein Biomarker Changes Following
Selective Inhibition of Janus Kinase 1 (JAK1)
by Filgotinib in Methotrexate Naïve Adults with
Moderately-to-Severely Active Rheumatoid
Arthritis (FINCH3)
Upadacitinib Monotherapy in Methotrexate Naïve
Patients with Rheumatoid Arthritis: Results at 72
Weeks from SELECT-EARLY
Incidence and Risk Factors for Herpes Zoster in
Rheumatoid Arthritis Patients Receiving Upadacitinib
Tofacitinib in the Treatment of Severe and
Refractory Behçet’s Disease: A Single-Centre
Experience in China
Improvements in Global Functioning and Health-
Related Quality of Life and their Association with
Disease Activity and Functional Improvement
in Patients with Active Ankylosing Spondylitis
Treated with Upadacitinib: Results from the
SELECT-AXIS 1 Trial
Impact of Filgotinib on Structural Lesions in
the Sacroiliac Joints at 12 Weeks in Patients
with Active Axial Spondyloarthritis: Magnetic
Resonance Imaging Data from the Double-Blind,
Randomised TORTUGA Trial
Safety of Tofacitinib Therapy in HBSAG Carriers
with Ankylosing Spondylitis: A Prospective Study
Chairman’s picks

Friday, June 5, 2020
ORAL PRESENTATIONS
Biological DMARDs in RA II
Dequeker, 10:15 – 10:55
OP0211
Time to Discontinuation of Tofacitinib and TNF
Inhibitors in Rheumatoid Arthritis Patients
with and without Methotrexate: Data from a
Rheumatoid Arthritis Cohort
Update on New Treatment Options for
Psoriatic Arthritis
Ansell, 10:15 – 10:55
OP0224
OP0225
Filgotinib Treatment leads to Rapid and Sustained
Reductions in Inflammatory Biomarkers in Patients
with Moderate to Severe Psoriatic Arthritis
Tofacitinib as Monotherapy following Methotrexate
Withdrawal in Patients with Psoriatic Arthritis
Previously Treated with Open-Label Tofacitinib +
Methotrexate: A Randomised, Placebo-Controlled
Substudy of OPAL Balance
Rheumatoid Arthritis - Non-Biologic
Treatment and Small Molecules
Wollheim, 10:15 – 10:55
OP0231
OP0233
OP0237
OP0238
Comparative Effectiveness of JAK-Inhibitors,
TNF-Inhibitors, Abatacept and IL-6 Inhibitors in
an International Collaboration of Registers of
Rheumatoid Arthritis Patients (The “JAK-Pot” Study)
Efficacy, Safety, and Pharmacodynamic Effects
of the Bruton’s Tyrosine Kinase Inhibitor,
Fenebrutinib (GDC-0853), in Moderate to Severe
Systemic Lupus Erythematosus in a Phase 2
Controlled Study
Thromboembolic Safety Profile of Tofacitinib and
Baricitinib: An Analysis of WHO VigiBase
Risk of Herpes Zoster in Patients with Rheumatoid
Arthritis under Biological, Targeted Synthetic, and
Conventional Synthetic DMARD Treatment
Novel Diagnostic and Therapeutic Approaches
in Paediatric Rheumatic Diseases
Rau, 10:15 – 10:50
OP0291
Tofacitinib for the Treatment of Polyarticular
Course Juvenile Idiopathic Arthritis: Results of a
Phase 3, Randomised, Double-Blind,
Placebo-Controlled Withdrawal Study
Friday, June 5, 2020
POSTERS
FRI0026
FRI0028
FRI0048
FRI0112
FRI0115
FRI0116
FRI0117
FRI0119
FRI0121
Proteomics Analysis Comparing the Mode of
Action of Upadacitinib and Adalimumab Head
to Head in RA Identifies Novel, Discrete Early
Immune Pathway Modulation in the
SELECT-COMPARE Phase 3 Study
JAK2 Mutation May Predict Response and Guide
First Line Treatment in Rheumatoid Arthritis
Number Needed to Treat to Achieve Minimum
Clinically Significant Differences in Patient-Reported
Outcomes in Patients Treated with Baricitinib
Risk of Malignancy with Non-TNFi Biologic or
Tofacitinib Therapy in Rheumatoid Arthritis:
A Meta-Analysis of Observational Studies
Filgotinib Provided Rapid and Sustained
Improvements in Functional Status, Pain, and
Health-Related Quality of Life, and Reduced
Fatigue Over Time in Patients with Rheumatoid
Arthritis who are Methotrexate-Naïve: Results
from the FINCH 3 Study
Comparable Efficacy and Safety of Two Regimens
of Rheumatoid Arthritis Treatment with Tofacitinib:
Data from Russian National Registry
Incidence Rate of Herpes Zoster in Rheumatoid
Arthritis Patients under Tofacitinib: Real-Life Data
from Turkey – HURBIO Registry
Title Use of JAK Inhibitors in the Treatment of
RA Patients in the Romanian Registry of
Rheumatic Diseases
Steroid-Sparing Effect of JAK Inhibitors in
Rheumatoid Arthritis Patients Followed up in a
Real Life Setting
Chairman’s picks

FRI0123
FRI0124
FRI0128
FRI0131
FRI0132
FRI0134
FRI0135
FRI0136
FRI0137
FRI0138
FRI0139
FRI0140
Safety Profile of Baricitinib for the Treatment of
Rheumatoid Arthritis up to 8.4 Years: An Updated
Integrated Safety Analysis
Efficacy and Safety of Baricitinib and Tofacitinib
in Rheumatoid Arthritis: Data from Real-World
Filgotinib Provided Rapid and Sustained
Improvements in Functional Status, Pain, Health-
Related Quality of Life, and Fatigue in Patients
with Rheumatoid Arthritis and Inadequate
Response to Methotrexate: Results from the
FINCH 1 Study
Sustainability of Response Between Upadacitinib and
Adalimumab Among Patients with Rheumatoid Arthritis
and Prior Inadequate Response to Methotrexate
Efficacy and Safety of Switching JAKinibs in
Rheumatoid Arthritis
Effect of JAK Inhibitors on Pain and Quality of
Life in Rheumatoid Arthritis Patients
Predictors for Short-Term Clinical Effectiveness
of Baricitinib in Rheumatoid Arthritis Patients in
Routine Clinical Practice: Data from a Japanese
Multicentre Registry
Peripheral Protein Biomarker Changes Following
Selective Inhibition of Janus Kinase 1 (JAK1) by
Filgotinib in Adults with Moderately-to-Severely
Active Rheumatoid Arthritis with Prior Inadequate
Response to Methotrexate (FINCH1)
Discontinuation of Baricitinib After Achieving Low
Disease Activity in Patients with Rheumatoid
Arthritis in Clinical Practice; A Multicentre
Observational Study
The Impact of Upadacitinib Versus Methotrexate or
Adalimumab on Individual and Composite Disease
Measures in Patients with Rheumatoid Arthritis
Filgotinib Provided Rapid and Sustained Relief of
Pain and Fatigue and Improved Health-Related
Quality of Life in Patients with Rheumatoid
Arthritis and Inadequate Response to Biologic
DMARDs: Results from the FINCH 2 Study
Impact of Baseline Demographics and
Disease Activity on Outcomes in Patients with
Rheumatoid Arthritis Receiving Upadacitinib
FRI0141
FRI0228
FRI0335
FRI0339
FRI0343
FRI0459
FRI0465
FRI0485
Characterisation of Serious Infections with
Upadacitinib in Patients with Rheumatoid Arthritis
Tofacitinib in the Treatment of Skin and
Musculoskeletal Involvement in Adult Patients with
Early Systemic Sclerosis, Evaluated by Ultrasound
The Effect of Tofacitinib on Residual Pain in
Patients with Psoriatic Arthritis
Long-Term Efficacy of the Oral Selective Janus
Kinase 1 Inhibitor Filgotinib in Psoriatic Arthritis:
Week 52 Response Patterns in Individual
Patients from an Open-Label Extension (OLE)
Study (EQUATOR2)
Efficacy and Safety of Filgotinib, A Selective Janus
Kinase 1 Inhibitor, in Patients with Active Psoriatic
Arthritis: Subgroup Analyses from A Randomised,
Placebo-Controlled, Phase 2 Trial (EQUATOR)
Tofacitinib Treatment in Recalcitrant JDM Patients
Tofacitinib Population Pharmacokinetics in
Children with Juvenile Idiopathic Arthritis: A Pooled
Analysis of Data from Three Clinical Studies
Risk of Progression of Idiopathic Pulmonary
Fibrosis to Connective Tissue Disease
Saturday, June 6, 2020
POSTERS
SAT0024
SAT0057
SAT0074
SAT0095
SAT0132
JAK-Inhibition with Baricitinib Inhibits Activation
of NLRP1/Caspase1/GDMSD Pyroptosis Pathway
in Rheumatoid Arthritis Synovial Fibroblasts
Predicting Inadequate Response to JAK Inhibitors by
Cluster Analysis in Patients with Rheumatoid Arthritis
Rheumatoid Arthritis at Treatment with bDMARD
or tsDMARD: Vaccination Rates and Incidence
of Respiratory Infectious Diseases, Results from
a Cohort
Real Life Severe Infections in Patients with
Rheumatoid Arthritis on Treatment with Biological
Therapy and JAKi
Does Janus Kinase Inhibition Induced Hyperlipidaemia
Associate with an Increase of Aortic Stiffness in
Patients with Arthritis? Preliminary Results of a
Prospective Pilot Study on Cardiovascular Risk
Chairman’s picks

SAT0136
SAT0139
SAT0140
SAT0141
SAT0142
SAT0143
SAT0145
SAT0149
SAT0151
SAT0152
SAT0153
Relative Efficacy and Safety of Tofacitinib,
Baricitinib, Upadacitinib, and Filgotinib, in
Comparison with Adalimumab in Patients with
Active Rheumatoid Arthritis: A Bayesian Network
Meta-Analysis of Randomised Controlled Trials
Age-based (<65 vs ≥65 years) Incidence of
Infections and Serious Infections in Tofacitinib-,
Adalimumab- and Placebo-treated Patients with
Rheumatoid Arthritis: A Post-hoc Analysis of Phase 3,
Phase 3 and Phase 3b/4 Tofacitinib Studies
Safety of Tofacitinib Therapy in HBSAG Carriers
with Rheumatoid Arthritis: A Prospective Study
Long-Term Effectiveness of Tofacitinib in Conventional
DMARDs Non-Responders with Rheumatoid Arthritis:
Results of Russian National Register
Matching Adjusted Indirect Comparison of
Filgotinib vs Tofacitinib in Moderate-to-Severe
Active Rheumatoid Arthritis Patients with
Inadequate Response to Methotrexate
A Phase 1 Study in Healthy Volunteers Exploring the
Safety, Pharmacokinetics and Pharmacodynamics of
ATI-450: A Novel Oral MK2 Inhibitor
Efficacy and Safety of Upadacitinib Monotherapy in
MTX Naïve Patients with Early Active RA Receiving
Treatment Within 3 Months of Diagnosis: A Post
Hoc Analysis Of the SELECT-EARLY
Exposure-Response Relationships for Efficacy and
Safety of Filgotinib and its Metabolite GS-829845
in Subjects with Rheumatoid Arthritis Based on
Phase 2 and Phase 3 Studies
Efficacy and Safety of Upadacitinib Versus Abatacept
in Patients with Active Rheumatoid Arthritis
and Prior Inadequate Response or Intolerance to
Biologic Disease-Modifying Anti-Rheumatic Drugs
(SELECT-CHOICE): A Double-Blind, Randomised
Controlled Phase 3 Trial
Efficacy of Baricitinib in Patients with
Moderate-to-Severe Rheumatoid Arthritis with
3 Years of Treatment: Results from a Long-Term Study
Gender Does Not Influence Clinical Response to
JAK Inhibitors in Rheumatoid Arthritis: an Italian
Multicentre Analysis
SAT0155
SAT0156
SAT0158
SAT0159
SAT0160
SAT0161
SAT0246
SAT0287
SAT0304
SAT0418
SAT0427
SAT0471
SAT0555
Whole Blood Transcriptional Changes Following
Selective Inhibition of Janus Kinase 1 (JAK1)
by Filgotinib in MTX-Naïve Adults with
Moderately-to-Severely Active Rheumatoid
Arthritis (RA) (FINCH3)
Effective of Baricitinib on Radiographic
Progression of Structural Joint Damage at 48
Weeks in Patients with Rheumatoid Arthritis in
Real-World Multicentre Clinical Data
Efficacy and Safety of Filgotinib in
Methotrexate-Naïve Patients with Rheumatoid
Arthritis: FINCH 3, 52-Week Results
Association Between Janus Kinase Inhibitors
and All-Cause Mortality in Patients with
Rheumatoid Arthritis
Efficacy and Safety of Upadacitinib in Patients
from China, Brazil, and South Korea with
Rheumatoid Arthritis who have had Inadequate
Response to Conventional Synthetic
Disease-Modifying Antirheumatic Drugs
The Analgesic Effect of Tofacitinib may have
Clinical Significance in Patients with Rheumatoid
Arthritis. Data from the Moscow Unified Register
of Arthritis (MUAR)
Targeting JAK/STAT Pathway in Takayasu’s Arteritis
Amplification of the Pro-Fibrotic JAK2-STAT3
Signalling Axis by TGFß-Induced Epigenetic
Silencing of SOCS3
Tofacitinib Inhibits TGF-B1-Induced Activated
Cell Functions of Myofibroblast in Human Lung
Fibroblast Populations
Effect of Tofacitinib Treatment on Active MRI
Sacroiliitis and Disease Activity Reduction in Psoriatic
Arthritis Patients. Data from Clinical Practice
Comparative Effectiveness of Tofacitinib and
Adalimumab in Psoriatic Arthritis Patients in Real
Clinical Practice
Effects of One Year Tofacitinib Therapy on Bone
Density and Biomarkers of Bone Turnover in
Rheumatoid Arthritis
Musculoskeletal Ultrasound in Monitoring
Response to JAKi in Rheumatoid Arthritis
Patients: Results From A Longitudinal Study
Chairman’s picks

SPONSORSHIP AND UNRESTRICTED EDUCATIONAL GRANTS FROM
Register for all this FREE content at
www.cytokinesignalling.com
www.cytokinesignalling.com
info@cytokinesignalling.com
Cytokine Signalling Forum
Cytokine Signalling Forum
@CytokineForum
Sponsorship and unrestricted educational grants from Lilly, AbbVie, Gilead, Galapagos and Pfizer S.R.L.
Developed under the auspices of the
University of Glasgow